This is the key, not sure why the "market" has not fully understood this:

Jacob P. Lalezari, M.D., Senior Science Advisor to CytoDyn, said:

Quote:

---

Treatment with leronlimab demonstrated reductions in both serious adverse events, as well as predictors of pulmonary collapse in patients with mild-to-moderate COVID-19. We initiated the study hoping to reduce flu-like symptoms, such as fever, cough, and muscle aches. In the end, use of leronlimab was not only correlated with improved symptom scores in patients with measurable symptoms at baseline, but also provided significant and consequential benefits on far more serious endpoints. Demonstrating these efficacy signals in a population with mostly mild illness at study entry bodes well for leronlimab’s activity in patients with more severe illness.

---

Let me repeat: in far more serious endpoints !!!. With p-value of p=0.0223 for Pete's sake !!.

What am I missing ???? . We have efficacy in moderate patients.

And, will have in Severe-Critical as well !!!.

I am sorry if some don't get it, but gave me the opportunity to add up at good SP even after the news

We are good !!!!